Anemia	B:C0002871
complicating	O
type	O
2	I:C0011860
diabetes	I:C0011860
:	O
Prevalence	O
,	O
risk	O
factors	I:C0035648
and	O
prognosis	O
.	O

Anemia	O
complicating	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
:	O
Prevalence	O
,	O
risk	O
factors	I:C0035648
and	O
prognosis	O
.	O

Anemia	O
complicating	O
type	O
2	I:C0011860
diabetes	I:C0011860
:	O
Prevalence	O
,	O
risk	B:C0035648
factors	I:C0035648
and	O
prognosis	O
.	O

Anemia	O
complicating	O
type	O
2	I:C0011860
diabetes	I:C0011860
:	O
Prevalence	O
,	O
risk	O
factors	I:C0035648
and	O
prognosis	B:C0033325
.	O

To	O
determine	O
the	O
prevalence	O
,	O
risk	B:C0035648
factors	I:C0035648
and	O
prognosis	O
of	O
anemia	O
in	O
representative	O
community	O
-	O
based	O
patients	O
with	O
type	O
2	I:C0011860
diabetes	I:C0011860
.	O

To	O
determine	O
the	O
prevalence	O
,	O
risk	O
factors	I:C0035648
and	O
prognosis	B:C0033325
of	O
anemia	O
in	O
representative	O
community	O
-	O
based	O
patients	O
with	O
type	O
2	I:C0011860
diabetes	I:C0011860
.	O

To	O
determine	O
the	O
prevalence	O
,	O
risk	O
factors	I:C0035648
and	O
prognosis	O
of	O
anemia	B:C0002871
in	O
representative	O
community	O
-	O
based	O
patients	O
with	O
type	O
2	I:C0011860
diabetes	I:C0011860
.	O

To	O
determine	O
the	O
prevalence	O
,	O
risk	O
factors	I:C0035648
and	O
prognosis	O
of	O
anemia	O
in	O
representative	B:C0030701
community	O
-	O
based	O
patients	O
with	O
type	O
2	I:C0011860
diabetes	I:C0011860
.	O

To	O
determine	O
the	O
prevalence	O
,	O
risk	O
factors	I:C0035648
and	O
prognosis	O
of	O
anemia	O
in	O
representative	O
community	O
-	O
based	O
patients	O
with	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
.	O

Data	O
from	O
the	O
Fremantle	B:C2603343
Diabetes	I:C2603343
Study	I:C2603343
Phase	I:C2603343
II	I:C2603343
(	O
FDS2	O
;	O
n=1551	O
,	O
mean	O
age	O
65.7	O
years	O
,	O
51.9	O
%	O
males	O
)	O
and	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
(	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
;	O
n=186	O
,	O
mean	O
age	O
70.2	O
years	O
,	O
50.0	O
%	O
males	O
)	O
cohorts	O
,	O
and	O
from	O
186	O
matched	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
participants	O
without	O
diabetes	O
,	O
were	O
analyzed	O
.	O

Data	O
from	O
the	O
Fremantle	O
Diabetes	I:C2603343
Study	I:C2603343
Phase	I:C2603343
II	I:C2603343
(	O
FDS2	B:C2603343
;	O
n=1551	O
,	O
mean	O
age	O
65.7	O
years	O
,	O
51.9	O
%	O
males	O
)	O
and	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
(	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
;	O
n=186	O
,	O
mean	O
age	O
70.2	O
years	O
,	O
50.0	O
%	O
males	O
)	O
cohorts	O
,	O
and	O
from	O
186	O
matched	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
participants	O
without	O
diabetes	O
,	O
were	O
analyzed	O
.	O

Data	O
from	O
the	O
Fremantle	O
Diabetes	I:C2603343
Study	I:C2603343
Phase	I:C2603343
II	I:C2603343
(	O
FDS2	O
;	O
n=1551	O
,	O
mean	O
age	O
65.7	O
years	O
,	O
51.9	O
%	O
males	O
)	O
and	O
Busselton	B:C2603343
Diabetes	I:C2603343
Study	I:C2603343
(	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
;	O
n=186	O
,	O
mean	O
age	O
70.2	O
years	O
,	O
50.0	O
%	O
males	O
)	O
cohorts	O
,	O
and	O
from	O
186	O
matched	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
participants	O
without	O
diabetes	O
,	O
were	O
analyzed	O
.	O

Data	O
from	O
the	O
Fremantle	O
Diabetes	I:C2603343
Study	I:C2603343
Phase	I:C2603343
II	I:C2603343
(	O
FDS2	O
;	O
n=1551	O
,	O
mean	O
age	O
65.7	O
years	O
,	O
51.9	O
%	O
males	O
)	O
and	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
(	O
Busselton	B:C2603343
Diabetes	I:C2603343
Study	I:C2603343
;	O
n=186	O
,	O
mean	O
age	O
70.2	O
years	O
,	O
50.0	O
%	O
males	O
)	O
cohorts	O
,	O
and	O
from	O
186	O
matched	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
participants	O
without	O
diabetes	O
,	O
were	O
analyzed	O
.	O

Data	O
from	O
the	O
Fremantle	O
Diabetes	I:C2603343
Study	I:C2603343
Phase	I:C2603343
II	I:C2603343
(	O
FDS2	O
;	O
n=1551	O
,	O
mean	O
age	O
65.7	O
years	O
,	O
51.9	O
%	O
males	O
)	O
and	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
(	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
;	O
n=186	O
,	O
mean	O
age	O
70.2	O
years	O
,	O
50.0	O
%	O
males	O
)	O
cohorts	B:C0599755
,	O
and	O
from	O
186	O
matched	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
participants	O
without	O
diabetes	O
,	O
were	O
analyzed	O
.	O

Data	O
from	O
the	O
Fremantle	O
Diabetes	I:C2603343
Study	I:C2603343
Phase	I:C2603343
II	I:C2603343
(	O
FDS2	O
;	O
n=1551	O
,	O
mean	O
age	O
65.7	O
years	O
,	O
51.9	O
%	O
males	O
)	O
and	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
(	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
;	O
n=186	O
,	O
mean	O
age	O
70.2	O
years	O
,	O
50.0	O
%	O
males	O
)	O
cohorts	O
,	O
and	O
from	O
186	O
matched	O
Busselton	B:C2603343
Diabetes	I:C2603343
Study	I:C2603343
participants	O
without	O
diabetes	O
,	O
were	O
analyzed	O
.	O

Data	O
from	O
the	O
Fremantle	O
Diabetes	I:C2603343
Study	I:C2603343
Phase	I:C2603343
II	I:C2603343
(	O
FDS2	O
;	O
n=1551	O
,	O
mean	O
age	O
65.7	O
years	O
,	O
51.9	O
%	O
males	O
)	O
and	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
(	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
;	O
n=186	O
,	O
mean	O
age	O
70.2	O
years	O
,	O
50.0	O
%	O
males	O
)	O
cohorts	O
,	O
and	O
from	O
186	O
matched	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
participants	B:C0679646
without	O
diabetes	O
,	O
were	O
analyzed	O
.	O

Data	O
from	O
the	O
Fremantle	O
Diabetes	I:C2603343
Study	I:C2603343
Phase	I:C2603343
II	I:C2603343
(	O
FDS2	O
;	O
n=1551	O
,	O
mean	O
age	O
65.7	O
years	O
,	O
51.9	O
%	O
males	O
)	O
and	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
(	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
;	O
n=186	O
,	O
mean	O
age	O
70.2	O
years	O
,	O
50.0	O
%	O
males	O
)	O
cohorts	O
,	O
and	O
from	O
186	O
matched	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
participants	O
without	O
diabetes	B:C0011847
,	O
were	O
analyzed	O
.	O

Data	O
from	O
the	O
Fremantle	O
Diabetes	I:C2603343
Study	I:C2603343
Phase	I:C2603343
II	I:C2603343
(	O
FDS2	O
;	O
n=1551	O
,	O
mean	O
age	O
65.7	O
years	O
,	O
51.9	O
%	O
males	O
)	O
and	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
(	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
;	O
n=186	O
,	O
mean	O
age	O
70.2	O
years	O
,	O
50.0	O
%	O
males	O
)	O
cohorts	O
,	O
and	O
from	O
186	O
matched	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
participants	O
without	O
diabetes	O
,	O
were	O
analyzed	B:C0936012
.	O

The	O
prevalence	O
of	O
anemia	B:C0002871
(	O
hemoglobin	O
≤	O
130g	O
/	O
L	O
males	O
,	O
≤	O
120g	O
/L	O
females	O
)	O
was	O
determined	O
in	O
each	O
sample	O
.	O

The	O
prevalence	O
of	O
anemia	O
(	O
hemoglobin	B:C0019046
≤	O
130g	O
/	O
L	O
males	O
,	O
≤	O
120g	O
/L	O
females	O
)	O
was	O
determined	O
in	O
each	O
sample	O
.	O

The	O
prevalence	O
of	O
anemia	O
(	O
hemoglobin	O
≤	O
130g	O
/	O
L	O
males	O
,	O
≤	O
120g	O
/L	O
females	O
)	O
was	O
determined	O
in	O
each	O
sample	B:C0178913
.	O

In	O
FDS2	B:C2603343
,	O
associates	O
of	O
anemia	O
were	O
assessed	O
using	O
multiple	O
logistic	O
regression	I:C0206031
and	O
Cox	O
proportional	I:C0010235
hazards	I:C0010235
modeling	I:C0010235
identified	O
predictors	O
of	O
death	O
during	O
4.3±1.2	O
years	O
post	O
-	O
recruitment	O
.	O

In	O
FDS2	O
,	O
associates	O
of	O
anemia	B:C0002871
were	O
assessed	O
using	O
multiple	O
logistic	O
regression	I:C0206031
and	O
Cox	O
proportional	I:C0010235
hazards	I:C0010235
modeling	I:C0010235
identified	O
predictors	O
of	O
death	O
during	O
4.3±1.2	O
years	O
post	O
-	O
recruitment	O
.	O

In	O
FDS2	O
,	O
associates	O
of	O
anemia	O
were	O
assessed	O
using	O
multiple	O
logistic	B:C0206031
regression	I:C0206031
and	O
Cox	O
proportional	I:C0010235
hazards	I:C0010235
modeling	I:C0010235
identified	O
predictors	O
of	O
death	O
during	O
4.3±1.2	O
years	O
post	O
-	O
recruitment	O
.	O

In	O
FDS2	O
,	O
associates	O
of	O
anemia	O
were	O
assessed	O
using	O
multiple	O
logistic	O
regression	I:C0206031
and	O
Cox	B:C0010235
proportional	I:C0010235
hazards	I:C0010235
modeling	I:C0010235
identified	O
predictors	O
of	O
death	O
during	O
4.3±1.2	O
years	O
post	O
-	O
recruitment	O
.	O

In	O
FDS2	O
,	O
associates	O
of	O
anemia	O
were	O
assessed	O
using	O
multiple	O
logistic	O
regression	I:C0206031
and	O
Cox	O
proportional	I:C0010235
hazards	I:C0010235
modeling	I:C0010235
identified	O
predictors	B:C0035648
of	O
death	O
during	O
4.3±1.2	O
years	O
post	O
-	O
recruitment	O
.	O

In	O
FDS2	O
,	O
associates	O
of	O
anemia	O
were	O
assessed	O
using	O
multiple	O
logistic	O
regression	I:C0206031
and	O
Cox	O
proportional	I:C0010235
hazards	I:C0010235
modeling	I:C0010235
identified	O
predictors	O
of	O
death	B:C0011065
during	O
4.3±1.2	O
years	O
post	O
-	O
recruitment	O
.	O

The	O
prevalence	O
of	O
anemia	B:C0002871
at	O
baseline	O
was	O
11.5	O
%	O
in	O
FDS2	O
participants	O
,	O
17.8	O
%	O
in	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
type	O
2	O
patients	O
and	O
5.4	O
%	O
in	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
participants	O
without	O
diabetes	O
.	O

The	O
prevalence	O
of	O
anemia	O
at	O
baseline	O
was	O
11.5	O
%	O
in	O
FDS2	B:C2603343
participants	O
,	O
17.8	O
%	O
in	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
type	O
2	O
patients	O
and	O
5.4	O
%	O
in	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
participants	O
without	O
diabetes	O
.	O

The	O
prevalence	O
of	O
anemia	O
at	O
baseline	O
was	O
11.5	O
%	O
in	O
FDS2	O
participants	B:C0679646
,	O
17.8	O
%	O
in	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
type	O
2	O
patients	O
and	O
5.4	O
%	O
in	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
participants	O
without	O
diabetes	O
.	O

The	O
prevalence	O
of	O
anemia	O
at	O
baseline	O
was	O
11.5	O
%	O
in	O
FDS2	O
participants	O
,	O
17.8	O
%	O
in	O
Busselton	B:C2603343
Diabetes	I:C2603343
Study	I:C2603343
type	O
2	O
patients	O
and	O
5.4	O
%	O
in	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
participants	O
without	O
diabetes	O
.	O

The	O
prevalence	O
of	O
anemia	O
at	O
baseline	O
was	O
11.5	O
%	O
in	O
FDS2	O
participants	O
,	O
17.8	O
%	O
in	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
type	O
2	O
patients	O
and	O
5.4	O
%	O
in	O
Busselton	B:C2603343
Diabetes	I:C2603343
Study	I:C2603343
participants	O
without	O
diabetes	O
.	O

The	O
prevalence	O
of	O
anemia	O
at	O
baseline	O
was	O
11.5	O
%	O
in	O
FDS2	O
participants	O
,	O
17.8	O
%	O
in	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
type	O
2	O
patients	O
and	O
5.4	O
%	O
in	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
participants	B:C0679646
without	O
diabetes	O
.	O

The	O
prevalence	O
of	O
anemia	O
at	O
baseline	O
was	O
11.5	O
%	O
in	O
FDS2	O
participants	O
,	O
17.8	O
%	O
in	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
type	O
2	O
patients	O
and	O
5.4	O
%	O
in	O
Busselton	O
Diabetes	I:C2603343
Study	I:C2603343
participants	O
without	O
diabetes	B:C0011847
.	O

In	O
FDS2	B:C2603343
,	O
163	O
of	O
178	O
patients	O
with	O
anemia	O
(	O
91.6	O
%	O
)	O
had	O
at	O
least	O
one	O
other	O
risk	O
factor	I:C0035648
(	O
serum	O
vitamin	I:C0427408
B12	I:C0427408
<	O
140	O
pmol	O
/	O
L	O
,	O
serum	O
ferritin	I:C0241012
<	O
30μg	O
/	O
L	O
and	O
/	O
or	O
transferrin	O
saturation	I:C1277709
<	O
20	O
%	O
,	O
serum	O
testosterone	I:C0428413
<	O
10	O
nmol	O
/	O
L	O
(	O
males	O
)	O
,	O
glitazone	O
therapy	O
,	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
(	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
)	O
<	O
60	O
mL	O
/	O
min	O
1.73	O
m	O
(	O
2	O
)	O
,	O
malignancy	O
,	O
hemoglobinopathy	O
)	O
.	O

In	O
FDS2	O
,	O
163	O
of	O
178	O
patients	O
with	O
anemia	B:C0002871
(	O
91.6	O
%	O
)	O
had	O
at	O
least	O
one	O
other	O
risk	O
factor	I:C0035648
(	O
serum	O
vitamin	I:C0427408
B12	I:C0427408
<	O
140	O
pmol	O
/	O
L	O
,	O
serum	O
ferritin	I:C0241012
<	O
30μg	O
/	O
L	O
and	O
/	O
or	O
transferrin	O
saturation	I:C1277709
<	O
20	O
%	O
,	O
serum	O
testosterone	I:C0428413
<	O
10	O
nmol	O
/	O
L	O
(	O
males	O
)	O
,	O
glitazone	O
therapy	O
,	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
(	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
)	O
<	O
60	O
mL	O
/	O
min	O
1.73	O
m	O
(	O
2	O
)	O
,	O
malignancy	O
,	O
hemoglobinopathy	O
)	O
.	O

In	O
FDS2	O
,	O
163	O
of	O
178	O
patients	O
with	O
anemia	O
(	O
91.6	O
%	O
)	O
had	O
at	O
least	O
one	O
other	O
risk	B:C0035648
factor	I:C0035648
(	O
serum	O
vitamin	I:C0427408
B12	I:C0427408
<	O
140	O
pmol	O
/	O
L	O
,	O
serum	O
ferritin	I:C0241012
<	O
30μg	O
/	O
L	O
and	O
/	O
or	O
transferrin	O
saturation	I:C1277709
<	O
20	O
%	O
,	O
serum	O
testosterone	I:C0428413
<	O
10	O
nmol	O
/	O
L	O
(	O
males	O
)	O
,	O
glitazone	O
therapy	O
,	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
(	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
)	O
<	O
60	O
mL	O
/	O
min	O
1.73	O
m	O
(	O
2	O
)	O
,	O
malignancy	O
,	O
hemoglobinopathy	O
)	O
.	O

In	O
FDS2	O
,	O
163	O
of	O
178	O
patients	O
with	O
anemia	O
(	O
91.6	O
%	O
)	O
had	O
at	O
least	O
one	O
other	O
risk	O
factor	I:C0035648
(	O
serum	B:C0427408
vitamin	I:C0427408
B12	I:C0427408
<	O
140	O
pmol	O
/	O
L	O
,	O
serum	O
ferritin	I:C0241012
<	O
30μg	O
/	O
L	O
and	O
/	O
or	O
transferrin	O
saturation	I:C1277709
<	O
20	O
%	O
,	O
serum	O
testosterone	I:C0428413
<	O
10	O
nmol	O
/	O
L	O
(	O
males	O
)	O
,	O
glitazone	O
therapy	O
,	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
(	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
)	O
<	O
60	O
mL	O
/	O
min	O
1.73	O
m	O
(	O
2	O
)	O
,	O
malignancy	O
,	O
hemoglobinopathy	O
)	O
.	O

In	O
FDS2	O
,	O
163	O
of	O
178	O
patients	O
with	O
anemia	O
(	O
91.6	O
%	O
)	O
had	O
at	O
least	O
one	O
other	O
risk	O
factor	I:C0035648
(	O
serum	O
vitamin	I:C0427408
B12	I:C0427408
<	O
140	O
pmol	O
/	O
L	O
,	O
serum	B:C0241012
ferritin	I:C0241012
<	O
30μg	O
/	O
L	O
and	O
/	O
or	O
transferrin	O
saturation	I:C1277709
<	O
20	O
%	O
,	O
serum	O
testosterone	I:C0428413
<	O
10	O
nmol	O
/	O
L	O
(	O
males	O
)	O
,	O
glitazone	O
therapy	O
,	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
(	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
)	O
<	O
60	O
mL	O
/	O
min	O
1.73	O
m	O
(	O
2	O
)	O
,	O
malignancy	O
,	O
hemoglobinopathy	O
)	O
.	O

In	O
FDS2	O
,	O
163	O
of	O
178	O
patients	O
with	O
anemia	O
(	O
91.6	O
%	O
)	O
had	O
at	O
least	O
one	O
other	O
risk	O
factor	I:C0035648
(	O
serum	O
vitamin	I:C0427408
B12	I:C0427408
<	O
140	O
pmol	O
/	O
L	O
,	O
serum	O
ferritin	I:C0241012
<	O
30μg	O
/	O
L	O
and	O
/	O
or	O
transferrin	B:C1277709
saturation	I:C1277709
<	O
20	O
%	O
,	O
serum	O
testosterone	I:C0428413
<	O
10	O
nmol	O
/	O
L	O
(	O
males	O
)	O
,	O
glitazone	O
therapy	O
,	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
(	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
)	O
<	O
60	O
mL	O
/	O
min	O
1.73	O
m	O
(	O
2	O
)	O
,	O
malignancy	O
,	O
hemoglobinopathy	O
)	O
.	O

In	O
FDS2	O
,	O
163	O
of	O
178	O
patients	O
with	O
anemia	O
(	O
91.6	O
%	O
)	O
had	O
at	O
least	O
one	O
other	O
risk	O
factor	I:C0035648
(	O
serum	O
vitamin	I:C0427408
B12	I:C0427408
<	O
140	O
pmol	O
/	O
L	O
,	O
serum	O
ferritin	I:C0241012
<	O
30μg	O
/	O
L	O
and	O
/	O
or	O
transferrin	O
saturation	I:C1277709
<	O
20	O
%	O
,	O
serum	B:C0428413
testosterone	I:C0428413
<	O
10	O
nmol	O
/	O
L	O
(	O
males	O
)	O
,	O
glitazone	O
therapy	O
,	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
(	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
)	O
<	O
60	O
mL	O
/	O
min	O
1.73	O
m	O
(	O
2	O
)	O
,	O
malignancy	O
,	O
hemoglobinopathy	O
)	O
.	O

In	O
FDS2	O
,	O
163	O
of	O
178	O
patients	O
with	O
anemia	O
(	O
91.6	O
%	O
)	O
had	O
at	O
least	O
one	O
other	O
risk	O
factor	I:C0035648
(	O
serum	O
vitamin	I:C0427408
B12	I:C0427408
<	O
140	O
pmol	O
/	O
L	O
,	O
serum	O
ferritin	I:C0241012
<	O
30μg	O
/	O
L	O
and	O
/	O
or	O
transferrin	O
saturation	I:C1277709
<	O
20	O
%	O
,	O
serum	O
testosterone	I:C0428413
<	O
10	O
nmol	O
/	O
L	O
(	O
males	O
)	O
,	O
glitazone	B:C1257987
therapy	O
,	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
(	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
)	O
<	O
60	O
mL	O
/	O
min	O
1.73	O
m	O
(	O
2	O
)	O
,	O
malignancy	O
,	O
hemoglobinopathy	O
)	O
.	O

In	O
FDS2	O
,	O
163	O
of	O
178	O
patients	O
with	O
anemia	O
(	O
91.6	O
%	O
)	O
had	O
at	O
least	O
one	O
other	O
risk	O
factor	I:C0035648
(	O
serum	O
vitamin	I:C0427408
B12	I:C0427408
<	O
140	O
pmol	O
/	O
L	O
,	O
serum	O
ferritin	I:C0241012
<	O
30μg	O
/	O
L	O
and	O
/	O
or	O
transferrin	O
saturation	I:C1277709
<	O
20	O
%	O
,	O
serum	O
testosterone	I:C0428413
<	O
10	O
nmol	O
/	O
L	O
(	O
males	O
)	O
,	O
glitazone	O
therapy	B:C0087111
,	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
(	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
)	O
<	O
60	O
mL	O
/	O
min	O
1.73	O
m	O
(	O
2	O
)	O
,	O
malignancy	O
,	O
hemoglobinopathy	O
)	O
.	O

In	O
FDS2	O
,	O
163	O
of	O
178	O
patients	O
with	O
anemia	O
(	O
91.6	O
%	O
)	O
had	O
at	O
least	O
one	O
other	O
risk	O
factor	I:C0035648
(	O
serum	O
vitamin	I:C0427408
B12	I:C0427408
<	O
140	O
pmol	O
/	O
L	O
,	O
serum	O
ferritin	I:C0241012
<	O
30μg	O
/	O
L	O
and	O
/	O
or	O
transferrin	O
saturation	I:C1277709
<	O
20	O
%	O
,	O
serum	O
testosterone	I:C0428413
<	O
10	O
nmol	O
/	O
L	O
(	O
males	O
)	O
,	O
glitazone	O
therapy	O
,	O
estimated	B:C3811844
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
(	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
)	O
<	O
60	O
mL	O
/	O
min	O
1.73	O
m	O
(	O
2	O
)	O
,	O
malignancy	O
,	O
hemoglobinopathy	O
)	O
.	O

In	O
FDS2	O
,	O
163	O
of	O
178	O
patients	O
with	O
anemia	O
(	O
91.6	O
%	O
)	O
had	O
at	O
least	O
one	O
other	O
risk	O
factor	I:C0035648
(	O
serum	O
vitamin	I:C0427408
B12	I:C0427408
<	O
140	O
pmol	O
/	O
L	O
,	O
serum	O
ferritin	I:C0241012
<	O
30μg	O
/	O
L	O
and	O
/	O
or	O
transferrin	O
saturation	I:C1277709
<	O
20	O
%	O
,	O
serum	O
testosterone	I:C0428413
<	O
10	O
nmol	O
/	O
L	O
(	O
males	O
)	O
,	O
glitazone	O
therapy	O
,	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
(	O
estimated	B:C3811844
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
)	O
<	O
60	O
mL	O
/	O
min	O
1.73	O
m	O
(	O
2	O
)	O
,	O
malignancy	O
,	O
hemoglobinopathy	O
)	O
.	O

In	O
FDS2	O
,	O
163	O
of	O
178	O
patients	O
with	O
anemia	O
(	O
91.6	O
%	O
)	O
had	O
at	O
least	O
one	O
other	O
risk	O
factor	I:C0035648
(	O
serum	O
vitamin	I:C0427408
B12	I:C0427408
<	O
140	O
pmol	O
/	O
L	O
,	O
serum	O
ferritin	I:C0241012
<	O
30μg	O
/	O
L	O
and	O
/	O
or	O
transferrin	O
saturation	I:C1277709
<	O
20	O
%	O
,	O
serum	O
testosterone	I:C0428413
<	O
10	O
nmol	O
/	O
L	O
(	O
males	O
)	O
,	O
glitazone	O
therapy	O
,	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
(	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
)	O
<	O
60	O
mL	O
/	O
min	O
1.73	O
m	O
(	O
2	O
)	O
,	O
malignancy	B:C4282132
,	O
hemoglobinopathy	O
)	O
.	O

In	O
FDS2	O
,	O
163	O
of	O
178	O
patients	O
with	O
anemia	O
(	O
91.6	O
%	O
)	O
had	O
at	O
least	O
one	O
other	O
risk	O
factor	I:C0035648
(	O
serum	O
vitamin	I:C0427408
B12	I:C0427408
<	O
140	O
pmol	O
/	O
L	O
,	O
serum	O
ferritin	I:C0241012
<	O
30μg	O
/	O
L	O
and	O
/	O
or	O
transferrin	O
saturation	I:C1277709
<	O
20	O
%	O
,	O
serum	O
testosterone	I:C0428413
<	O
10	O
nmol	O
/	O
L	O
(	O
males	O
)	O
,	O
glitazone	O
therapy	O
,	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
(	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
)	O
<	O
60	O
mL	O
/	O
min	O
1.73	O
m	O
(	O
2	O
)	O
,	O
malignancy	O
,	O
hemoglobinopathy	B:C0019045
)	O
.	O

More	O
anemic	B:C0857322
than	O
non-anemic	O
FDS2	O
patients	O
died	O
(	O
28.7	O
%	O
versus	O
8.0	O
%	O
;	O
P	O
<	O
0.001	O
)	O
.	O

More	O
anemic	O
than	O
non-anemic	B:C0857322
FDS2	O
patients	O
died	O
(	O
28.7	O
%	O
versus	O
8.0	O
%	O
;	O
P	O
<	O
0.001	O
)	O
.	O

More	O
anemic	O
than	O
non-anemic	O
FDS2	B:C2603343
patients	O
died	O
(	O
28.7	O
%	O
versus	O
8.0	O
%	O
;	O
P	O
<	O
0.001	O
)	O
.	O

After	O
adjustment	O
for	O
other	O
independent	O
predictors	B:C0035648
(	O
age	O
as	O
time	O
-	O
scale	O
,	O
male	O
sex	O
,	O
Aboriginality	O
,	O
marital	O
status	O
,	O
smoking	O
,	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
)	O
,	O
anemia	O
was	O
associated	O
with	O
a	O
57	O
%	O
increase	O
in	O
mortality	O
(	O
P=0.015	O
)	O
.	O

After	O
adjustment	O
for	O
other	O
independent	O
predictors	O
(	O
age	O
as	O
time	O
-	O
scale	O
,	O
male	O
sex	O
,	O
Aboriginality	B:C1704258
,	O
marital	O
status	O
,	O
smoking	O
,	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
)	O
,	O
anemia	O
was	O
associated	O
with	O
a	O
57	O
%	O
increase	O
in	O
mortality	O
(	O
P=0.015	O
)	O
.	O

After	O
adjustment	O
for	O
other	O
independent	O
predictors	O
(	O
age	O
as	O
time	O
-	O
scale	O
,	O
male	O
sex	O
,	O
Aboriginality	O
,	O
marital	O
status	O
,	O
smoking	O
,	O
estimated	B:C3811844
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
)	O
,	O
anemia	O
was	O
associated	O
with	O
a	O
57	O
%	O
increase	O
in	O
mortality	O
(	O
P=0.015	O
)	O
.	O

After	O
adjustment	O
for	O
other	O
independent	O
predictors	O
(	O
age	O
as	O
time	O
-	O
scale	O
,	O
male	O
sex	O
,	O
Aboriginality	O
,	O
marital	O
status	O
,	O
smoking	O
,	O
estimated	O
glomerular	I:C3811844
filtration	I:C3811844
rate	I:C3811844
)	O
,	O
anemia	B:C0002871
was	O
associated	O
with	O
a	O
57	O
%	O
increase	O
in	O
mortality	O
(	O
P=0.015	O
)	O
.	O

Type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
at	O
least	O
doubles	O
the	O
risk	O
of	O
anemia	O
but	O
other	O
mostly	O
modifiable	O
risk	O
factors	I:C0035648
are	O
usually	O
present	O
.	O

Type	O
2	I:C0011860
diabetes	I:C0011860
at	O
least	O
doubles	O
the	O
risk	O
of	O
anemia	B:C0002871
but	O
other	O
mostly	O
modifiable	O
risk	O
factors	I:C0035648
are	O
usually	O
present	O
.	O

Type	O
2	I:C0011860
diabetes	I:C0011860
at	O
least	O
doubles	O
the	O
risk	O
of	O
anemia	O
but	O
other	O
mostly	O
modifiable	O
risk	B:C0035648
factors	I:C0035648
are	O
usually	O
present	O
.	O

Type	O
2	I:C0011860
diabetes	I:C0011860
at	O
least	O
doubles	O
the	O
risk	O
of	O
anemia	O
but	O
other	O
mostly	O
modifiable	O
risk	O
factors	I:C0035648
are	O
usually	O
present	B:C0150312
.	O

Anemia	B:C0002871
is	O
associated	O
with	O
an	O
increased	O
risk	I:C2749787
of	I:C2749787
death	I:C2749787
after	O
adjustment	O
for	O
other	O
predictors	O
.	O

Anemia	O
is	O
associated	O
with	O
an	O
increased	B:C2749787
risk	I:C2749787
of	I:C2749787
death	I:C2749787
after	O
adjustment	O
for	O
other	O
predictors	O
.	O

Anemia	O
is	O
associated	O
with	O
an	O
increased	O
risk	I:C2749787
of	I:C2749787
death	I:C2749787
after	O
adjustment	O
for	O
other	O
predictors	B:C0035648
.	O

